Silence Therapeutics (NASDAQ:SLN - Get Free Report) announced its earnings results on Thursday. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.72, Zacks reports. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. The company had revenue of $25.08 million for the quarter, compared to analyst estimates of $6.77 million.
Silence Therapeutics Stock Down 4.0 %
SLN traded down $0.18 during trading on Monday, hitting $4.32. 211,451 shares of the stock were exchanged, compared to its average volume of 321,734. Silence Therapeutics has a 1-year low of $4.06 and a 1-year high of $27.72. The stock has a fifty day moving average price of $5.63 and a two-hundred day moving average price of $11.74. The firm has a market capitalization of $129.30 million, a P/E ratio of -2.75 and a beta of 1.05.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on SLN shares. The Goldman Sachs Group initiated coverage on Silence Therapeutics in a report on Tuesday, February 11th. They issued a "sell" rating and a $6.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a research note on Wednesday, January 29th. Chardan Capital reissued a "buy" rating and issued a $55.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, December 10th. William Blair reaffirmed an "outperform" rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Finally, BMO Capital Markets reiterated an "outperform" rating on shares of Silence Therapeutics in a report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $45.00.
Get Our Latest Stock Analysis on Silence Therapeutics
Silence Therapeutics Company Profile
(
Get Free Report)
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Read More
Before you consider Silence Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silence Therapeutics wasn't on the list.
While Silence Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
